Gonzalo J Acosta1, Spandana Brown1, Ashkan M Zand1, Abhishek Kansara2, Archana Sadhu1. 1. Department of Internal Medicine, Division of Endocrinology, Houston Methodist Hospital, 6565 Fannin St. Suite 1101, Houston, TX, 77030, USA. 2. Department of Internal Medicine, Division of Endocrinology, Houston Methodist Hospital, 6565 Fannin St. Suite 1101, Houston, TX, 77030, USA. ahkansara@houstonmethodist.org.
Abstract
PURPOSE OF REVIEW: To highlight global advancements in diabetes technology and compare available technologies and device approval processes in the USA and Europe and their impact on safety and innovation. RECENT FINDINGS: The last two decades have seen a rapid growth in diabetes technology driven by the impetus to improve glycemic control, avoid complications of insulin therapy, improve quality of life, and hand more autonomy to individuals with diabetes. Meanwhile, changes to regulatory processes in the USA and Europe aim to facilitate entry of new devices into the marketplace. Major strides have been made in digitization of insulin pens, continuous glucose monitors and their integration with insulin pumps, automated insulin delivery systems, and closed-loop insulin pump systems. The centralized regulatory body in the USA and more decentralized approval bodies in Europe have led to differences in the rate of market availability of diabetes devices. While both US and Europe systems have different advantages and disadvantages in device approval, they continue to struggle with balancing accelerated device access with adequate clinical evidence and monitoring to ensure safety of such devices.
PURPOSE OF REVIEW: To highlight global advancements in diabetes technology and compare available technologies and device approval processes in the USA and Europe and their impact on safety and innovation. RECENT FINDINGS: The last two decades have seen a rapid growth in diabetes technology driven by the impetus to improve glycemic control, avoid complications of insulin therapy, improve quality of life, and hand more autonomy to individuals with diabetes. Meanwhile, changes to regulatory processes in the USA and Europe aim to facilitate entry of new devices into the marketplace. Major strides have been made in digitization of insulin pens, continuous glucose monitors and their integration with insulin pumps, automated insulin delivery systems, and closed-loop insulin pump systems. The centralized regulatory body in the USA and more decentralized approval bodies in Europe have led to differences in the rate of market availability of diabetes devices. While both US and Europe systems have different advantages and disadvantages in device approval, they continue to struggle with balancing accelerated device access with adequate clinical evidence and monitoring to ensure safety of such devices.
Entities:
Keywords:
Approval process; Continuous glucose monitor; Diabetes technology; Europe; Insulin pump; United States
Authors: Lutz Heinemann; G Alexander Fleming; John R Petrie; Reinhard W Holl; Richard M Bergenstal; Anne L Peters Journal: Diabetes Care Date: 2015-04 Impact factor: 19.112
Authors: Bruce Bode; Roy W Beck; Dongyuan Xing; Lisa Gilliam; Irl Hirsch; Craig Kollman; Lori Laffel; Katrina J Ruedy; William V Tamborlane; Stuart Weinzimer; Howard Wolpert Journal: Diabetes Care Date: 2009-08-12 Impact factor: 19.112